Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

A technology of globin and uterus, which is applied in the application field of recombinant human uteroglobin in the treatment of inflammatory and fibrotic diseases, and can solve the problem that uteroglobin cannot inhibit the ECM invasion activity and other problems

Inactive Publication Date: 2001-11-21
克拉拉根有限公司 +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Uteroglobin fails to suppress ECM invasion viability of cells lacking UG-binding protein

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
  • Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
  • Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0162] Recombinant human uteroglobin can be obtained by the method of Mantile et al. (1993). One male and one female P. cynocephalus weighing approximately 400 g were weighed after delivery by hysterotomy (C-section) at 142 days of conception. This is the established model of RDS (Coalson, J.J. et al., The Baboon Model of BPD II: Pathological Features. Exp. Mol. Pathol. 37:355-350 (1982)).

[0163] Following delivery, infants were anesthetized with Ketamine (10 mg / kg) and intubated with a 2.5 mm diameter endotracheal tube. Blood gases and blood pressure were monitored through an arterial line injected percutaneously into the radial artery. A deeper venous line is placed percutaneously into the saphenous vein to infuse fluids, antibodies, and medications. Animals were housed in a servo-controlled infrared incubator, ventilated using a standard time-period, pressure-regulated ventilator with a humidifier, and maintained at 36-37°C. The initial setting is FiO 2 1.0, the rate ...

Embodiment 2

[0167] Embodiment 2. In vitro utilization of soluble PLA 2 Inhibit hydrolysis of artificial surfactants

[0168] In vitro utilization of soluble PLA 2 , rhUG can inhibit the hydrolysis of artificial surfactants. Survanta is an artificial surfactant preparation extracted from the lungs of cattle and is indicated for the treatment of preterm neonates with respiratory distress syndrome (ARDS) and adults with respiratory distress syndrome (ARDS). Survanta is the first group of soluble PLA 2 Hydrolyzed, such as porcine, pancreatic PLA 2 , characterized as a substrate with the ability to compete with the fluorescent lecithin substrate and produce arachidonic acid product.

[0169] Survanta is an in vitro substrate that can be treated by the first group of soluble PLA 2 degradation. In vitro, Survanta can be rapidly absorbed by PLA in the extracellular fluid of human lungs 2 degradation. RhUG can inhibit the degradation of Survanta in vitro. Embodiment 3. Construction of u...

Embodiment 3

[0169] Survanta is an in vitro substrate that can be treated by the first group of soluble PLA 2 degradation. In vitro, Survanta can be rapidly absorbed by PLA in the extracellular fluid of human lungs 2 degradation. RhUG can inhibit the degradation of Survanta in vitro. Embodiment 3. Construction of uteroglobin knockout mice

[0170] The purpose of establishing a transgenic uteroglobin knockout mouse was to determine the role of uteroglobin in mammalian physiology and to generate a model of uteroglobin therapy in several inflammatory clinical diseases. The first step was to construct an appropriate DNA vector with which the endogenous uteroglobin gene in mice could be targeted and blocked. A 3.2 kb BamHI-EcoRI DNA fragment derived from the uteroglobin agent gene of the 129 / SVI mouse strain (RAY, 1993) containing exon 3 and flanking sequences was subcloned into p PNW The corresponding site of the vector, as described by Lei et al. (1996). Transform the NotI and XhoI res...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Compositions and methods for preventing or treating primary cancer cell growth and tumor metastasis, as well as stimulation of hematopoiesis are described and claimed. The present invention also relates to methods of treating cancer and uteroglobin receptor-related conditions by targeting a uteroglobin receptor with recombinant human uteroglobin (rhUG). Also disclosed and claimed are methods of purifying a uteroglobin receptor and methods of using such receptor(s) to identify uteroglobin structural analogs and UG-receptor ligands.

Description

[0001] Notes on cross-references to related applications [0002] This application is a continuation-in-part of U.S. Patent Application Serial No. 09 / 087,210, filed May 28, 1998, which is a continuation-in-part of U.S. Patent Application Serial No. 08 / 864,357, filed May 28, 1997 . The filing dates of the above two patents are March 28, 1998 and March 28, 1997, respectively. Moreover, the disclosures of the aforementioned patents are hereby incorporated by reference. field of invention [0003] Briefly, the present invention relates to the treatment of inflammatory and fibrotic diseases with natural human uteroglobin (hUG) or recombinant human uteroglobin (rhUG). Novel physiological roles and therapies for UG (hUG or rhUG) have been identified. In particular, the invention relates to inhibition of PLA by administration of hUG or rhUG 2 s and / or prevent fibronectin precipitation for the treatment of inflammatory and fibrotic diseases. In addition, the present invention prov...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/50A61K38/00A61K38/17A61P11/00A61P13/12A61P27/00A61P29/00A61P31/00A61P35/00A61P37/02A61P43/00C07K14/46C07K14/47C07K16/18C07K17/00G01N33/15G01N33/53G01N33/566
CPCA01K2217/075C07K14/4721A61K38/1709A61P11/00A61P13/12A61P27/00A61P29/00A61P31/00A61P35/00A61P37/02A61P43/00A61K38/17
Inventor A·皮隆A·B·慕克吉Z·张
Owner 克拉拉根有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com